Literature DB >> 20599743

Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro.

Karthik Raman1, Balagurunathan Kuberan.   

Abstract

Heparan sulfate proteoglycans (HSPGs) play vital roles in many steps of angiogenesis under physiological and pathological conditions. HSPGs on endothelial cell surfaces act as co-receptors for a variety of pro-angiogenic growth factors such as FGF and VEGF and anti-angiogenic factors such as endostatin. However, the fine structural requirements of these binding interactions are dependent on the sulfation patterns of HSPGs. Previous studies have shown that Heparitinases, heparin lyases isolated from Flavobacterium heparinum, can cleave heparan sulfate chains. These enzymes have been shown to reduce tumor-derived neovascularization in vivo in mice. However, the results from these experiments could not conclusively pinpoint the origin of the HS fragments. Thus, in this study we utilized an in vitro assay to assess the differential effects of Heparitinase I (Hep I) and Heparitinase III (Hep III) on endothelial tube formation. Hep III was found to be a more potent inhibitor of tube formation than Hep I. In conclusion, differential cleavage of endothelial cell surface bound HS can affect the extent of inhibition of tube formation. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599743      PMCID: PMC2924581          DOI: 10.1016/j.bbrc.2010.06.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis.

Authors:  Dongfang Liu; Zachary Shriver; Ganesh Venkataraman; Yosuf El Shabrawi; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.

Authors:  L Borsig; R Wong; J Feramisco; D R Nadeau; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Authors:  H Gitay-Goren; S Soker; I Vlodavsky; G Neufeld
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

4.  Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165.

Authors:  S Gengrinovitch; B Berman; G David; L Witte; G Neufeld; D Ron
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

5.  Fluorescent-tagged heparan sulfate precursor oligosaccharides to probe the enzymatic action of heparitinase I.

Authors:  Ponnusamy Babu; Balagurunathan Kuberan
Journal:  Anal Biochem       Date:  2009-09-02       Impact factor: 3.365

6.  6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture.

Authors:  Noriko Sugaya; Hiroko Habuchi; Naoko Nagai; Satoko Ashikari-Hada; Koji Kimata
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

7.  Purification and characterization of heparin lyases from Flavobacterium heparinum.

Authors:  D L Lohse; R J Linhardt
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

8.  The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

Authors:  Yang Yang; Veronica MacLeod; Yuemeng Dai; Yekaterina Khotskaya-Sample; Zachary Shriver; Ganesh Venkataraman; Ram Sasisekharan; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Israel Vlodavsky; Larry J Suva; Joshua Epstein; Shmuel Yaccoby; John D Shaughnessy; Bart Barlogie; Ralph D Sanderson
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

Review 9.  PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.

Authors:  Vito Ferro; Keith Dredge; Ligong Liu; Edward Hammond; Ian Bytheway; Caiping Li; Ken Johnstone; Tomislav Karoli; Kat Davis; Elizabeth Copeman; Anand Gautam
Journal:  Semin Thromb Hemost       Date:  2007-07       Impact factor: 4.180

10.  Purification and characterization of heparinase from Flavobacterium heparinum.

Authors:  V C Yang; R J Linhardt; H Bernstein; C L Cooney; R Langer
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

View more
  5 in total

1.  Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis.

Authors:  Karthik Raman; Masayuki Ninomiya; Thao Kim Nu Nguyen; Yasuhiro Tsuzuki; Mamoru Koketsu; Balagurunathan Kuberan
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

2.  Discovery of novel sulfonated small molecules that inhibit vascular tube formation.

Authors:  Karthik Raman; Rajesh Karuturi; Vimal P Swarup; Umesh R Desai; Balagurunathan Kuberan
Journal:  Bioorg Med Chem Lett       Date:  2012-04-16       Impact factor: 2.823

3.  Fractone-heparan sulphates mediate FGF-2 stimulation of cell proliferation in the adult subventricular zone.

Authors:  V Douet; A Kerever; E Arikawa-Hirasawa; F Mercier
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

4.  A glycan-based approach to therapeutic angiogenesis.

Authors:  Jie Shi Chua; Vy M Tran; Mausam Kalita; Maritza V Quintero; Orlando Antelope; Geethu Muruganandam; Yukio Saijoh; Balagurunathan Kuberan
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

5.  Isolation and characterization of HepP: a virulence-related Pseudomonas aeruginosa heparinase.

Authors:  Nyaradzo Dzvova; Jane A Colmer-Hamood; John A Griswold; Abdul N Hamood
Journal:  BMC Microbiol       Date:  2017-12-16       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.